Skip to main content
OpenTrials
Completed

NCT Number: NCT01390935

SUrvey of Guideline Adherence for Treatment of Systolic Heart Failure in Real World

The purpose of this study is to survey the guideline compliance of the cardiologists in the treatment of systolic heart failure in Korea

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

GSK Investigational Site

Seoul, 135-710, South Korea

About this study

Major improvement in the medical management of CHF has been achieved in the past decades.

But there is no doubt that prognosis of heart failure patients remains poor. The compliance to the standard treatment can be one of reasons. But very little data concerning this in Korea is available.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects admitted to hospital with systolic heart failure(LVEF under 45%) in 2009
  • Subjects, age 20 or/and above
  • Subjects admitted to hospital (emergency area, to internal medicine or to cardiology wards, CCU or intensive care) with dyspnea and verification of heart failure based on following criteria;
  • Symptoms typical of heart failure : breathlessness at rest or on exercise, fatigue, tiredness, ankle swelling and Signs typical of heart failure : tachycardia, tachypnoea, pulmonary rales, pleural effusion, raised jugular venous pressure, peripheral oedema, hepatomegaly
  • Objective evidence of a structural or functional abnormality of the heart at rest : cardiomegaly, third heard sound, cardiac murmurs, abnormality on the echocardiogram, raised natriuretic peptide concentration

Exclusion criteria

  • Subject who expired during hospitalization

Treatment and study plan

guideline adherence

Other

guideline adherence of physician

Other names: ACEI, ARB, BB, aldosterone antagonist

Primary outcomes

  1. Mean of modified Guideline Adherence Indicator(mGAI-3)

    Time frame: 1year

    Modified percentage based on each participant's condition

Secondary outcomes

  1. Percentage of participants with each class drug prescribed

    Time frame: 1year

    ARB, BB, ACE-I, aldosterone antagonist

  2. Percentage of participants with daily target dose reached

    Time frame: 1year

    ARB, BB, ACE-I, aldosterone antagonist

  3. Percentage of all cause mortality

    Time frame: 1year

    All cause mortality in 1-year after treatment of systolic heart failure

  4. Percentage of All cause hospitalization

    Time frame: 1year

    All cause hospitalization in 1-year after treatment of systolic heart failure

  5. Mean of mortality or rehospitalization rate according to mGAI-3

    Time frame: 1year

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Official study title

SUrvey of Guideline Adherence for Treatment of Systolic Heart Failure in Real WorldMulticenter, Retrospective Observation Study in Korea

Acronym: SUGAR

Important dates

Study start
2011
Primary completion
2012
Study completion
2012
First posted
Jul 11, 2011
Registry last updated
Nov 30, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.